Dennis W T Nilsen
Overview
Explore the profile of Dennis W T Nilsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nilsen D, Kontny F, Ten Cate H
Front Cardiovasc Med
. 2024 Jun;
11:1432580.
PMID: 38873268
No abstract available.
2.
Nilsen D, Aarsetoey R, Poenitz V, Ueland T, Aukrust P, Michelsen A, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Apr;
21:200264.
PMID: 38596196
Introduction: Chemokines mediate recruitment and activation of leucocytes. Chemokine ligand 18 (CCL18) is mainly expressed by monocytes/macrophages and dendritic cells. It is highly expressed in chronic inflammatory diseases, and locally...
3.
Andersen T, Ueland T, Aukrust P, Nilsen D, Grundt H, Staines H, et al.
Front Cardiovasc Med
. 2023 Sep;
10:1191055.
PMID: 37731526
Background: Extracellular matrix (ECM) is an integral player in the pathophysiology of a variety of cardiac diseases. Cardiac ECM is composed mainly of collagen, of which type 1 is the...
4.
5.
Nilsen D, Roysland M, Ueland T, Aukrust P, Michelsen A, Staines H, et al.
Thromb Haemost
. 2023 Jan;
123(5):510-521.
PMID: 36588289
Background: Vorapaxar has been shown to reduce cardiovascular mortality in post-myocardial infarction (MI) patients. Pharmacodynamic biomarker research related to protease-activated receptor-1 (PAR-1) inhibition with vorapaxar in humans has short follow-up...
6.
Myhre P, Kalstad A, Tveit S, Laake K, Schmidt E, Smith P, et al.
J Intern Med
. 2022 Jan;
291(5):637-647.
PMID: 34982486
Background: The cardiovascular benefit from n-3 polyunsaturated fatty acids (PUFAs) after acute myocardial infarction (AMI) is controversial, and the importance of serum eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) concentrations...
7.
Aarsetoy R, Ueland T, Aukrust P, Michelsen A, Leon de la Fuente R, Grundt H, et al.
BMC Cardiovasc Disord
. 2021 Oct;
21(1):496.
PMID: 34649504
Background: Complement activation has been associated with atherosclerosis, atherosclerotic plaque destabilization and increased risk of cardiovascular events. Complement component 7 (CC7) binds to the C5bC6 complex which is part of...
8.
Aarsetoy R, Ueland T, Aukrust P, Michelsen A, Leon de la Fuente R, Ponitz V, et al.
J Intern Med
. 2021 Jul;
290(4):894-909.
PMID: 34237166
Background: Plasma levels of angiopoietin-2 (ANGPT2) and angiopoietin-like 4 protein (ANGPTL4) reflect different pathophysiological aspects of cardiovascular disease. We evaluated their association with outcome in a hospitalized Norwegian patient cohort...
9.
Aarsetoy R, Ten Cate H, Spronk H, Van Oerle R, Aarsetoy H, Staines H, et al.
Thromb Res
. 2021 Jun;
204:1-8.
PMID: 34089982
Background: Cardiac arrest and cardiopulmonary resuscitation (CPR) are associated with activated coagulation and microvascular fibrin deposition with subsequent multiorgan failure and adverse outcome. Objectives: Activated Factor XI-antithrombin (FXIa-AT) complex, activated...
10.
Samuelsen P, Eggen A, Steigen T, Wilsgaard T, Kristensen A, Skogsholm A, et al.
PLoS One
. 2021 Mar;
16(3):e0247358.
PMID: 33661918
Introduction: Bleeding is a concern after percutaneous coronary intervention (PCI) and subsequent dual antiplatelet therapy (DAPT). We herein report the incidence and risk factors for major bleeding in the Norwegian...